45,714 Shares in Coherus Oncology, Inc. $CHRS Acquired by International Assets Investment Management LLC

International Assets Investment Management LLC bought a new position in shares of Coherus Oncology, Inc. (NASDAQ:CHRS) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 45,714 shares of the biotechnology company’s stock, valued at approximately $33,000.

Other institutional investors have also recently added to or reduced their stakes in the company. CWM LLC lifted its stake in Coherus Oncology by 96.6% during the first quarter. CWM LLC now owns 49,793 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 24,468 shares during the last quarter. Cerity Partners LLC lifted its stake in Coherus Oncology by 84.0% during the first quarter. Cerity Partners LLC now owns 54,676 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 24,953 shares during the last quarter. Ieq Capital LLC lifted its stake in Coherus Oncology by 52.5% during the first quarter. Ieq Capital LLC now owns 75,020 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 25,837 shares during the last quarter. Nuveen LLC purchased a new stake in Coherus Oncology during the first quarter worth approximately $77,000. Finally, Deutsche Bank AG lifted its stake in Coherus Oncology by 198.9% during the first quarter. Deutsche Bank AG now owns 117,983 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 78,508 shares during the last quarter. Hedge funds and other institutional investors own 72.82% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on CHRS shares. Weiss Ratings restated a “sell (d)” rating on shares of Coherus Oncology in a research note on Friday. Maxim Group raised Coherus Oncology from a “hold” rating to a “buy” rating and set a $4.00 price target on the stock in a research report on Thursday, September 4th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $4.51.

Coherus Oncology Trading Down 1.2%

NASDAQ:CHRS opened at $1.65 on Friday. The firm has a market cap of $191.78 million, a P/E ratio of 1.06 and a beta of 0.97. The company has a current ratio of 1.44, a quick ratio of 1.43 and a debt-to-equity ratio of 0.31. The stock’s 50 day simple moving average is $1.46 and its 200-day simple moving average is $1.08. Coherus Oncology, Inc. has a 12-month low of $0.66 and a 12-month high of $2.43.

About Coherus Oncology

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.